Lyell (LYEL) CSO Gary K. Lee Sells 131 Shares

What Happened

• Gary K. Lee, Chief Scientific Officer of Lyell Immunopharma (LYEL), disposed of 131 shares in an S-coded sale on 2026-08-10. The Form 4 reports a weighted average sale price of $14.34 and total proceeds of approximately $1,879.
• Per the filing footnote, the shares were automatically sold to cover tax withholding resulting from the settlement of vested restricted stock units (RSUs), a routine post-vesting tax-withholding sale rather than an open-market investment decision.

Key Details

• Transaction date: 2026-08-10; Form 4 filed 2026-08-11 (timely filing).
• Reported weighted average price: $14.34; reported price range: $14.22–$14.34 (see footnote F2).
• Shares disposed: 131; reported proceeds: ~$1,879.
• Footnote F1: Sale was automatic to satisfy tax withholding on vested RSUs.
• Footnote F2: Price shown is a weighted average; breakdown by price is available upon request to the SEC/issuer/security holder.
• Shares owned after the transaction: not specified in the supplied filing details.

Context

• Sales to cover tax withholding on vested RSUs are common and typically routine administrative transactions, not necessarily a signal of the insider’s view on the company. Purchases by insiders generally carry more weight as a positive signal for investors.